# Poor outcome in second kidney transplantation: a delayed event

K Trébern-Launay, Y Foucher, M Giral, C Legendre, H Kreis, M Kessler, M Ladrière, N Kamar, L Rostaing, V Garrigue, G Mourad, E Morelon, JP Soulillou, J Dantal

katy.launay@univ-nantes.fr

Institute Transplantation Urology and Nephrology, Inserm U643, Nantes

Department of Research in Biostatistics EA4275, University of Nantes, France

ESOT - September 6, 2011





# Are patient and graft survival of first and second kidney transplant recipients comparable or not?



## The study endpoint was the patient and graft survival



## **Inclusion Criteria**

#### **DIVAT database**

- Centers: Nantes, Necker, Nancy, Toulouse, Montpellier or Lyon
- Adult recipients
- First or second grafts
- Transplanted from 1996
- Under MMF and steroids at transplantation



### Analysis methods were standard



## **Cox model: adjustment on confounding factors**

#### **Recipient factors**

- Gender and age
- Causal nephropathy
- Anti-class I and anti-class II PRA
- Comorbidities (history of diabetes, cardiovascular disease, hypertension, dyslipemia, B or C hepatitis and malignancy)

#### **Donor factors**

Age

#### **Transplantation factors**

- Transplantation period
- HLA-A-B-DR mismatches
- Relation donor/recipient
- Cold ischemia time
- Induction therapy

## **Results - Differences in demographic characteristics**

Variables	First grafts N = 2462 (79.3%)	Second grafts N = 641 (20.7%)		
Recipient ≥ 55 years of age	44.7%		30.4%	
Donor age ≥ 55 years of age	42.9%		32.6%	
History of diabetes	12.0%		6.4%	
More than 4 HLA-A-B-DRmismatches	15.8%		6.6%	
Potentially recurrent causal nephropathy	30.2%		42.4%	
Cold ischemia time ≥ 24 hours	27.1%		37.0%	
Positive anti-class I PRA	17.1%		62.7%	
Positive anti-class II PRA	16.7%		74.7%	
Depleting induction therapy	35.9%		78.3%	

PRA, panel reactive antibody; HLA, human leukocyte antigen

# Results - Patient and graft survival is significantly lower for second transplant recipients



Post-transplantation time (years)

# The Cox model confirmed that second transplantation is an independant risk factor of graft failure after 4 years

Variables	Hazard Ratio	95% CI	р
Graft rank before 4 post-graft years (2 / 1)	1.05	0.75-1.47	0.7830
Graft rank after 4 post-graft years (2 / 1)	2.18	1.35-3.50	*0.0013
Transplantation period (< 2005 / ≥ 2005)	1.32	1.01-1.72	*0.0427
Recipient gender (male / female)	1.01	0.82-1.25	0.9364
Recipient age (≥ 55 years / < 55 years)	1.49	1.17-1.89	*0.0012
Causal nephropathy (recurrent / non recurrent)	1.13	0.91-1.39	0.2734
History of diabetes (positive / negative)	1.28	0.96-1.71	0.0947
History of hypertension (positive / negative)	0.86	0.67-1.12	0.2665
History of vascular disease (positive / negative)	1.05	0.80-1.38	0.7449
History of cardiac disease (positive / negative)	1.34	1.09-1.65	*0.0057
History of dyslipemia (positive / negative)	1.16	0.93-1.45	0.1971
History of malignancy (positive / negative)	1.17	0.84-1.62	0.3483
History of B/C hepatitis (positive / negative)	1.06	0.72-1.57	0.7587
Level of HLA-ABDR mismatch ( $\geq 5 / < 5$ )	1.30	0.99-1.71	0.0639
Anti-class I PRA (positive / negative)	1.43	1.11-1.85	*0.0055
Anti-class II PRA (positive / negative)	0.98	0.74-1.30	0.8970
Induction therapy (depleting / non depleting)	0.88	0.69-1.12	0.2852
Cold ischemia time (≥ 24h / < 24h)	1.18	0.95-1.45	0.1370
Donor age (≥ 55 years / < 55 years)	1.19	0.94-1.49	0.1459
Relation recipient/donor (deceased donor / living donor)	2.19	1.35-3.57	*0.0015
BMI (≥ 30 kg.m <sup>-2</sup> / < 30 kg.m <sup>-2</sup> )	1.54	1.14-2.09	*0.0050
Donor EBV serology (positive / negative)	1.80	1.17-2.77	*0.0076

\* p<0.05

Is the higher risk for second grafts after 4 years related to:

- a higher frequency of acute rejection episodes (ARE)?
- a higher frequency of steroid-resistant ARE?



#### Cox model

#### HR = 1.01 (p = 0.9675)

Second transplant recipients don't tend to have a higher ARE occurrence than the first ones

#### HR = 1.27 (p = 0.4087)

Second transplant recipients tend to have a higher risk of steroidresistant ARE (not significant)

## **Conclusion and prospects**



Is the occurrence of donor specific antibodies higher and/or earlier for second transplant recipients? ⇒ Case control study